In the News

Read the latest news on OCG to stay up-to-date on new research findings and important announcements.

TARGET
January 20, 2013

Neuroblastoma is a type of cancer that arises in the developing sympathetic nervous system and is diagnosed primarily in infants and children. The study reported a low median frequency of exonic...

CTD²
December 21, 2012

This work combined loss-of-function screening data mined from Project Achilles, a project partially supported by CTD², and gene expression/copy number analyses from the Cancer Cell Line...

TARGET
December 08, 2012

Dr. Charles Mullighan surveys the large collection of genetic alterations revealed from these studies in childhood ALL and explains how some of these alterations may be used to understand and...

TARGET
June 13, 2012

From AACR Cancer Discovery: NCI's Therapeutically Applicable Research to Generate Effective Treatments Initiative, an effort begun in 2006 to use sequencing technologies to identify new drug...

CGCI
May 24, 2012

Using RNA sequencing (RNA-seq), Scott et al. discovered a novel recurrent gene fusion between TBL1XR1 and TP63 in diffuse large B-cell lymphoma (DLBCL). Further analysis revealed the TBL1XR1/...

TARGET
March 01, 2012

Don't miss TARGET and other OCG programs at the American Association for Cancer Research (AACR) Annual Meeting 2012!

TARGET
October 11, 2011

Javed Khan, M.D., a molecular biologist at the National Cancer Institute (NCI) discusses programs such as TARGET (Therapeutically Applicable Research to Generate Effective Treatments), the...

TARGET
February 06, 2011

Although five-year survival rates for childhood acute lymphoblastic leukemia (ALL) are now over 80% in most industrialized countries, not all children have benefited equally from this progress....

CGCI
December 16, 2010

Medulloblastoma (MB) is the most common malignant brain tumor of children. To identify the genetic alterations in this tumor type, we searched for copy number alterations using high-density...

TARGET
August 10, 2010

To resolve the genetic heterogeneity within pediatric high-risk B-precursor acute lymphoblastic leukemia (ALL), a clinically defined poor-risk group with few known recurring cytogenetic...

Pages